Comprehensive medication guide to Molnupiravir including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$50 copay on most commercial insurance plans and Medicare Part D (typically Tier 1 placement). Commercially insured patients may reduce cost to as little as $10 using the Merck manufacturer savings coupon.
Estimated Cash Pricing
$1,042–$1,100 retail for a 5-day course (40 × 200 mg capsules) of brand-name Lagevrio; no generic available. Commercially insured patients can pay as little as $10 with the Merck Lagevrio Savings Coupon.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Molnupiravir, sold under the brand name Lagevrio, is an oral antiviral medication developed by Merck in collaboration with Ridgeback Biotherapeutics. It is authorized in the United States under an FDA Emergency Use Authorization (EUA) — not a full FDA approval — for the treatment of mild-to-moderate COVID-19 in adults at high risk for disease progression.
The drug was originally developed at Emory University to treat influenza and was repurposed for COVID-19 when the pandemic began. The UK Medicines and Healthcare products Regulatory Agency (MHRA) was the first regulatory authority to authorize it, in November 2021. The FDA followed with its EUA on December 23, 2021.
Molnupiravir is taken as 800 mg (4 × 200 mg capsules) orally every 12 hours for 5 days. It must be started within 5 days of symptom onset. No generic version exists in the United States, and it is not a DEA-scheduled controlled substance.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Molnupiravir is a prodrug that is rapidly converted in the body to its active metabolite, N4-hydroxycytidine (NHC), and then to NHC-triphosphate (NHC-TP). NHC-TP is incorporated into viral RNA by the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) — the enzyme responsible for copying the viral genome.
Once incorporated, NHC-TP introduces copying errors throughout the viral genome because it can mimic two different RNA bases (cytidine and uridine), causing the virus to make mistakes during replication. Unlike normal errors, these NHC-TP-induced mistakes are not corrected by the virus's proofreading enzymes. As the errors accumulate across multiple replication cycles, the viral genome becomes so corrupted that newly made virus copies are unable to infect cells — a process called lethal mutagenesis or error catastrophe.
Because this mechanism targets the highly conserved RdRp enzyme, molnupiravir retains activity against all major SARS-CoV-2 variants, including Omicron and its subvariants. Crucially, molnupiravir is not metabolized through CYP450 liver enzymes, which is why it has no known drug-drug interactions — a major clinical advantage over Paxlovid.
200 mg — capsule
Four capsules (800 mg total) taken by mouth every 12 hours for 5 days
800 mg — dose (4 capsules)
Standard twice-daily dose; 40 total capsules per treatment course
As of 2026, molnupiravir (Lagevrio) is not listed on the FDA's official Drug Shortage Database and Merck continues commercial manufacturing. However, pharmacy-level availability is inconsistent. Because molnupiravir is the third-line COVID-19 treatment — behind Paxlovid and remdesivir — pharmacies stock it in smaller quantities and less predictably than first-line options.
Localized stock gaps are most common at smaller and independent pharmacies, in rural areas, and during seasonal COVID-19 surges. Large chain pharmacies (CVS, Walgreens, Walmart) are most likely to carry it, but even these may run low during peak demand. The drug's high retail price (over $1,000 per course) also discourages some smaller pharmacies from stocking it routinely.
Because molnupiravir must be started within 5 days of symptom onset, finding it quickly is critical. medfinder is a paid service that calls pharmacies near you to find which ones have your medication in stock, then texts you the results — so you can go directly to the pharmacy that has it ready to fill.
Molnupiravir is not a controlled substance, so any licensed prescriber can write a prescription without special DEA authorization. However, prescribers must comply with the FDA EUA requirements, including verifying pregnancy status in females of childbearing potential, providing the patient Fact Sheet, and documenting the clinical rationale.
Primary Care Physicians (MDs and DOs)
Infectious Disease Specialists
Nurse Practitioners (NPs) with prescribing authority
Physician Assistants (PAs) with collaborating agreements
Urgent Care Providers
Note: Unlike Paxlovid, molnupiravir cannot be prescribed directly by pharmacists. A prescription from a licensed medical provider is required. Telehealth providers can prescribe molnupiravir in all 50 states, and the federal Test to Treat program allows patients to be tested and receive a prescription in one visit. Platforms such as Teladoc, MDLive, and Amazon Clinic offer COVID-19 evaluations that may result in a molnupiravir prescription when clinically appropriate.
No. Molnupiravir (Lagevrio) is not a DEA-scheduled controlled substance. It is classified as a prescription-only medication but has no special controlled substance scheduling requirements. Any licensed prescriber — including physicians, nurse practitioners, and physician assistants — can write a prescription for molnupiravir without special DEA authorization.
Unlike controlled substances such as opioids or stimulants, molnupiravir does not have refill restrictions based on scheduling. However, it does operate under specific FDA Emergency Use Authorization (EUA) requirements, including mandatory pregnancy status verification, patient fact sheet distribution, and documentation of clinical rationale when prescribed over higher-priority treatment options.
Molnupiravir is generally well-tolerated. In the Phase 3 MOVe-OUT clinical trial, the most commonly reported side effects were:
Diarrhea
Nausea
Dizziness
Boxed Warning — Fetal Harm: Based on animal studies, molnupiravir may cause birth defects or embryo-fetal death. Not recommended in pregnancy. Requires pregnancy verification before use.
Bone and Cartilage Toxicity (Animal Studies): Observed in animals with repeated dosing; reason for prohibition in patients under 18.
Serious Allergic Reaction (Rare): Hives, difficulty breathing, facial swelling — seek emergency care immediately.
Know what you need? Skip the search.
Paxlovid (nirmatrelvir/ritonavir)
FDA-approved first-line oral COVID-19 antiviral. More effective than molnupiravir at viral clearance but has significant drug-drug interactions due to ritonavir component. Prescribed by pharmacists in some states.
Remdesivir (Veklury)
FDA-approved IV antiviral for COVID-19. Second-line recommendation for outpatients. Requires 3 consecutive daily infusions at a clinic. No drug interactions. Made by Gilead Sciences.
Pemivibart (Pemgarda)
Monoclonal antibody for pre-exposure prophylaxis in severely immunocompromised patients who are unlikely to respond adequately to COVID-19 vaccines. Not a treatment for active infection.
Prefer Molnupiravir? We can find it.
No known drug-drug interactions
minorAs of 2026, no clinically significant drug-drug interactions have been identified for molnupiravir. This is a major advantage over Paxlovid. Always report all medications to your provider.
Alcohol (indirect)
minorNo pharmacological interaction, but heavy alcohol use may suppress immune function and worsen dizziness (a known molnupiravir side effect). Avoid heavy alcohol during COVID-19 treatment.
Pregnancy (contraindicated)
majorNot a drug-drug interaction but a critical contraindication. Animal studies show potential fetal harm. Molnupiravir is not recommended during pregnancy (boxed warning).
Molnupiravir (Lagevrio) fills an important gap in COVID-19 treatment: it is the only oral antiviral with no known drug-drug interactions, making it the critical option for high-risk patients who cannot safely take Paxlovid. While it is considered less effective than Paxlovid overall, for the patients who need it most — those on complex medication regimens, transplant recipients, patients on blood thinners — it can be a life-saving medication.
The biggest practical challenge with molnupiravir in 2026 is pharmacy availability. Because it is a third-line treatment with lower prescription volume, it is stocked inconsistently at the individual pharmacy level. Patients must act quickly — the 5-day treatment window is unforgiving, and every hour spent searching for the medication reduces its potential benefit.
If you or someone you care for has been prescribed molnupiravir and is struggling to find it, medfinder can help. It's a paid service that calls pharmacies near you to identify which ones have your medication in stock and texts you the results — saving valuable time in a narrow treatment window.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini